Byotrol Share Discussion Threads

[brownson] 31/10/2020 19:44

In my humble opinion they lack the skills or ambition to make any serious money even if there are 5 waves. Although on the face of it the 6 hour hand sanitiser seems a good idea, in practice, it has little advantage. No sensible person will avoid hand washing because they have used invirtu, so it gets washed off. Cheap alcohol gels will win the day. Byotrol 24 could be great but they like to keep it secret in case anyone wants to buy it. Then they would have the problem of actually making it. Really an awful lot of bother. So the years of underachievement will continue until the products become irrelevant. A very British story

[football] 31/10/2020 18:22

Does Byotrol now get a 2nd bite of the cherry with the 2nd wave?

[wisecat2] 30/10/2020 14:18

Brownstuff appears on any share weakness. Never held a share but is extremely jealous of the management. Spent most of his life I expect with the NHS a mop in one hand and a bucket in the other. Probably blames the company for being replaced by a much better cleaner.

[1gw] 30/10/2020 13:37

The circular/notice of AGM has appeared.

[slicethepie] 30/10/2020 13:10

All 2000 of them, not giving him that job sweeping the carpark must have really hurt!

[tradertrev] 30/10/2020 11:28

brownstuff zero added value, just subjective opinions on management - filtered

[brownson] 30/10/2020 08:41

Now down about 40% from the high. DT and team should be ashamed.

[brownson] 29/10/2020 13:14

It will soon be back at that level. It's sad that such great products are pretty much invisible courtesy of incompetent management. I don't think DT is much better than his predecessor. Lacks the ability to take this forward but I think it's too late anyway. They have missed the golden opportunity.

[1gw] 29/10/2020 11:45

And on the current shareprice, we're still above the 5.93p level it was at just before the Midas tip was published (17th August).

Since then we haven't had a lot of company news - yes the FY20 results have been published, but there have been no further TUs for this year other than the 24th September one with the prelims quoting the reduced order book at the time. We have had the news of the Solvay launch which personally I saw as huge, but I don't know that it would have resonated with the market other than with those who have been following the company for some time.

So to some extent I think both the pop in share price following the Midas tip, and the current decline are consequences, at least in part, of the shareholder base. Very few obvious big institutional shareholders to provide stability by selling into rises and buying the dips, and probably a lot of retail shareholders chasing the tip and perhaps now selling down to preserve profits or limit losses in the relative absence of news.

The AGM statement will be a chance to give a more comprehensive financial/trading update to the market, although they could still choose to wait until the 1H results, probably in late November or early December.

[1gw] 29/10/2020 11:27

I guess it depends on your entry point and your perspective going forwards.

From my entry point in 2017 (and having followed the company for some years before that) it seems that management have positioned the company very well for where they now find themselves. David Traynor took over in 2013 I think and as far as I can see he and his team rescued the company, rebuilt it and have positioned it now to reap the benefits as it scales up.

Through the supply chain troubles early in the pandemic they chose to favour health services and long-standing customers, selling to them at fair prices, rather than trying to "profiteer" by selling to the highest bidder and I applaud them for that.

Going forward the Solvay deal looks like it could turn into a blockbuster for byotrol, and I think both Tristel and SC Johnson have potential to become serious profit-contributors in the years to come. Byotrol24 is more difficult to judge at the moment, but I think it has to have been the right decision to license rather than invest in the US market. The development of the Boots agreement in the UK, with the byotrol branding on the product, also looks like a good thing.

So maybe some would have made more in terms of short-term sales at high margin through the worst of the pandemic shortages, but would that have positioned the company well to thrive in the long-term?

[1gw] 29/10/2020 10:54

- and with the auditors (still listed as Mazars under Advisors);
- and the link on the front page to "Latest Annual Report" (FY19).

[riddlerone] 29/10/2020 10:46

Goes with the Shareholder Information

"Last updated 23 September 2019"

[1gw] 29/10/2020 09:28

Up about 300% year-to-date. Not many LTH's would complain about that, I think.

[brownson] 29/10/2020 08:56

And yet the price drifts inexorably downwards.Great science, clueless in every other way.

[riddlerone] 28/10/2020 18:57

I have been hoping that DT is going to be able to update the market to the upside at the AGM or before.Looks promising when you see new products appearing on partners sites.

[riddlerone] 28/10/2020 18:41

igw ,didn't notice that new size.Had a look at availability and every store locally to me has them in stock.If thats replicated Uk wide then its been quite an order to fill.

[1gw] 28/10/2020 18:02

New size option as well - 600ml pack. If these two developments are signs of the trailed expansion of the Boots relationship, is it not worthy of an RNS - even if it has to be an "RNS Reach" one?

[riddlerone] 28/10/2020 08:19

Looks like Boots are offering various Immunity and protection bundles with guess who's sanitiser!! The good part of that as well is that its the first items from the search page.As they say every little helps.

[riddlerone] 27/10/2020 14:32

Like it football every site has them removed with
"The Entire range of Virapro Hand Sanitiser has been recalled by the Department of Agriculture. If you purchased this product you should stop using immediately"

[football] 27/10/2020 13:40

Virapro hand sanitiser: NI health service checks after Irish safety recall

[1gw] 27/10/2020 10:25

Just listening back to the InvestorMeet presentation, a couple of highlights for me were on Boots and Solvay.

On Boots, I heard:
"...it's doing very nicely for us and I really like the validation the association with Boots gives us and I expect we'll be expanding that relationship in the very near future."

which sounds like we might expect an announcement before long.

And on Solvay (Actizone):
"They gave us usage rights. Anything they develop in this sphere we can brand byotrol and sell it in our own right."

- so fantastic optionality there to leverage any success that Solvay get in their sales and marketing campaign by introducing byotrol-branded products.

[riddlerone] 27/10/2020 07:58

Sadly I think this article reinforces the changes that everyone has to make as this is here for the long term.

[1gw] 26/10/2020 10:28

I don't think either of those 2 comments are fair.

On the advertising point, they have been running byotrol on the proverbial shoestring for years, and would have felt I am sure that (material) consumer-targeted advertising was a luxury they could ill-afford. Things are perhaps beginning to change now as they become cash-generative. Even so, on the hand sanitiser, you might expect Boots to be better-placed to fund "mass market" advertising/awareness campaigns if they thought there would be a net benefit (gain to them on non-alcohol based sanitiser sales vs any loss in sales on alcohol-based) - byotrol should then be able to leverage that for its own brand. If Boots isn't prepared to fund advertising/awareness, then byotrol can look to do something, I would hope, but it would have to be more specialist and targeted given the relative lack of scale.

And on IP, byotrol has to pick its battles. The sale to Solvay was both pragmatic as a way of funding the rest of the business, and strategic given the greater resources Solvay could then put behind product development (and now sales & marketing). The licensing to SC Johnson (and Tristel) came only after years of trying to crack hospital sales on their own and realising they didn't have the necessary resources to compete effectively selling into the NHS. And licensing into the US was common sense - few shareholders would have supported them betting the company on cracking the US market given the scale of investment that would have been required.

Licensing to Boots is a bit different in that they have the byotrol brand on the product and so success by Boots will make it easier to scale up their own retail offering, should they choose to go that way, or to license elsewhere.

All those commercial arrangements now position the company with the realistic prospect of years of positive cashflow ahead of it, which allows it to consider more seriously investing in its own branded sales in various markets.

[football] 25/10/2020 15:30

Think the company have got into the mindset of selling the IP and then taking a small percentage rather than going after the whole 100-percent